| Literature DB >> 32082293 |
Giuliana Lo Cascio1, Marcello Vincenzi2, Fabio Soldani2, Elena De Carolis3, Laura Maccacaro1, Annarita Sorrentino1, Gianpaolo Nadali4, Simone Cesaro5, Michele Sommavilla6, Valentina Niero7, Laura Naso1, Anna Grancini8, Anna Maria Azzini2, Maurizio Sanguinetti3, E Tacconelli2, Giuseppe Cornaglia1.
Abstract
INTRODUCTION: New fungal species are increasingly reported in immunocompromised patients. Saprochaete clavata (S. clavata), an ascomycetous fungus formerly called Geotrichum clavatum, is intrinsically resistant to echinocandins and is often misidentified.Entities:
Keywords: MALDI-TOF; Saprochaete; outbreak; whole-genome sequencing; yeast sepsi
Year: 2020 PMID: 32082293 PMCID: PMC7004961 DOI: 10.3389/fmicb.2020.00084
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
FIGURE 1Workflow used to produce the phylogenetic tree of isolated Saprochaete.
FIGURE 2Epidemiological curve of Saprochaete clavata infections. The cases are designated with letters which identify the isolate, with boxes corresponding to the date of the first positive blood culture.
Characteristics of the Saprochaete cases.
| Sex female add a line with number of male patients and controls? | 1 (14.3) | 17 (48.6) |
| Mean age (SD) | 41.1 (26.1) | 51.0 (22.0) |
| 0–40 | 3 (42.7) | 8 (22.3) |
| 41–50 | 1 (14.3) | 4 (11.4) |
| 51–60 | 1 (14.3) | 9 (25.7) |
| 61–70 | 2 (28.6) | 10 (28.6) |
| >70 | – | 4 (11.4) |
| Transfer to other UO what is UO? | 2 (28.6) | 10 (28.6) |
| Acute myeloid leukemia | 2 (28.6) | 10 (28.6) |
| Chronic myeloid leukemia | – | 2 (5.7) |
| Lymphoma | 2 (28.6) | 14 (40.0) |
| Multiple myeloma | – | 3 (8.6) |
| Other | 3 (42.9) | 6 (17.1) |
| Charlson co-morbidity score, media (DS) | 3 (1.8) | 4.3 (2.0) |
| 0–3 | 4 (57.1) | 11 (31.4) |
| 4–7 | 3 (42.9) | 21 (60.0) |
| 8–11 | – | 3 (8.6) |
| Barthel scale, mean (SD) | 86.7 (21.8) | 88.2 (19.6) |
| Dead, | 3 (42.9) | 2 (5.7) |
| Presence of CVC during recovery | 7 (100) | 32 (31.4) |
| 0–20 | 2 (28.6) | 18 (51.4) |
| 21–40 | – | 10 (28.6) |
| >40 | 5 (71.4) | 7 (20.0) |
| Days of CVC, mean (IQR) | 64(18–78) | 20(15–30) |
| Mechanical ventilation | 1 (14.3) | 2 (5.7) |
| Bladder catheter | 3 (42.9) | 9 (25.7) |
| Chemotherapy | 7 (100) | 29 (82.9) |
| Immunosuppression | 7 (100) | 24 (68.6) |
| Antibiotics | 7 (100) | 33 (94.3) |
| Aminoglycosides | 6 (85.7) | 11 (31.4) |
| Days with aminoglycosides, mean (SD) | 11.4 (11.6) | 0 (0.7) |
| Penicillin with beta-lactamases inhibitor | 5 (71.4) | 17 (48.6) |
| Days with penicillin with BL inhibitor, mean (SD) | 5.5 (5.1) | 4.0 (5.9) |
| Cephalosporins 3–4° gen. | 3 (42.9) | 13 (37.1) |
| Days with cephalosporins 3–4° gen., mean (SD) | 7.1 (11.7) | 3.9 (7.1) |
| Fluorochinolons | 2 (28.2) | 13 (37.1) |
| Days with fluorochinolons, mean (SD) | 3.8 (9.4) | 7.0 (11.1) |
| Glycopeptides, | 4 (57.1) | 9 (25.7) |
| Days with glycopeptides, mean(SD) | 8.4 (12.0) | 2.7(85.2) |
| Meropenem | 5 (71.4) | 5 (14.3) |
| Days with meropenem, mean (SD) | 7.3 (10.0) | 2.1 (8.6) |
| Co-trimoxazole | 1 (14.3) | 5 (14.3) |
| Days with co-trimoxazole, mean (SD) | 0.3 (0.8) | 0.6 (1.7) |
| Antifungals | 4 (57.1) | 26 (74.3) |
| Amphotericin | 3 | 4 |
| Days with amphotericin B, mean (SD) | 2.9 (4.3) | 2.6 (9.9) |
| Azols | 2 | 25 |
| Days with azols, mean (SD) | 9.4 (19.5) | 13.6 (11.5) |
| Echinocandins | 2 | 2 |
| Days with echinocandins, mean (SD) | 3 (5.5) | 0.4 (1.8) |
| HSCT | 2 (28.6) | 8 (22.9) |
| Days from the HSCT, mean (SD) | 33 (22.6) | 20.1 (9.0) |
| Proton pump inhibitors (PPI) | 4 (57.1) | 24 (68.6) |
| Neutropenia | 7 (100) | 30 (85.7) |
| Nadir of neutrophils, mean (DS) | 11.4 (3.89) | 121 (262.5) |
| Days with neutropenia, mean (DS) | 23 (15.1) | 9.9 (6.8) |
| 0–10 | 3 (42.3) | 18 (60.0) |
| 11–20 | – | 10 (33.3) |
| >20 | 4 (57.1) | 2 (6.7) |
| Growth factors | 5 (71.4) | 21 (60.0) |
| Mucositis | 3 (42.9) | 7 (20.0) |
| Diarrhea | 6 (85.7) | 17 (48.6) |
| Transfusion with RC | 7 (100) | 30 (85.7) |
| Number of red cell transfusion, mean (SD) | 12.4 (9.7) | 4.1 (3.3) |
| Plasma transfusion | 4 (57.1) | 4 (11.4) |
| Number of plasma transfusion, mean (SD) | 3.1 (3.5) | 0.3(1.0) |
| Platelet transfusion | 7 (100) | 26 (74.3) |
| Number of platelet transfusion, mean (SD) | 14.4(11.7) | 2.8(3.6) |
Conditioned univariate logistic regression analysis for Saprochaete-positive blood cultures risk factors.
| Aminoglycosides use | 12.5 (1.4–113.2) | 0.025 |
| Meropenem use | 8.8 (1.7–47.0) | 0.011 |
| Duration of neutropenia in days | 1.1 (1.0–1.18) | 0.011 |
| Plasma transfusion | 13.7 (1.4–128.7) | 0.022 |
| Number of transfused platelet unity | 1.4 (1.0–1.8) | 0.029 |
| Duration of aminoglycosides therapy (days) | 1.2 (1.0–1.4) | 0.040 |
FIGURE 3Microscopic morphology of Saprochaete clavata in positive blood cultures showing yeast-like cells.
FIGURE 4Culture of Saprochaete clavata on Sabouraud dextrose agar.
FIGURE 5Correlation-based dendrograms obtained by (A) MALDI-TOF MS (Bruker Daltonics) and (B) MS-Vitek Saramis (bioMerieux, Marcy l’Etoile, France).
Details of sequenced fragments for each strain of Saprochaete isolated from Verona and Milan.
| RS235 | 16,282,394 | 14,335,384 | 216.59 |
| RP402 | 24,467,857 | 22,739,883 | 331.26 |
| AA102 | 16,692,742 | 14,796,911 | 218.73 |
| CG108 | 13,899,852 | 12,314,272 | 187.31 |
| TP525 | 14,058,887 | 12,582,330 | 186.30 |
| TN293 | 24,179,648 | 18,491,452 | 278.89 |
| ZY075 | 22,790,265 | 21,525,722 | 330.71 |
| MI409 | 19,684,314 | 18,707,031 | 287.14 |
| MI691 | 19,061,001 | 18,077,681 | 280.81 |
| MI031 | 21,889,597 | 20,360,099 | 311.55 |
FIGURE 6Phylogenetic tree produced by SNprelate, z-score at supported nodes.
FIGURE 7Phylogenetic tree produced by Ape/Phangorn, bootstrap value at nodes.
FIGURE 8Principal component analysis of 199 informative SNPs.